Supreme Court To Hear Arguments On Scope Of “Bolar Amendment” April 20
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma companies and BIO ask the high court not to create a “bright line” test for determining what types of research are protected. The appeals court decision in Merck KGaA v. Integra found that the Waxman/Hatch “safe harbor” protection from patent infringement claims did not extend to preclinical research.